256 related articles for article (PubMed ID: 37459922)
1. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
Song Q; Zhang X; Liu W; Wei H; Liang W; Zhou Y; Ding Y; Ji F; Ho-Kwan Cheung A; Wong N; Yu J
J Hepatol; 2023 Dec; 79(6):1352-1365. PubMed ID: 37459922
[TBL] [Abstract][Full Text] [Related]
2. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
[TBL] [Abstract][Full Text] [Related]
3. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid.
Lau HC; Zhang X; Ji F; Lin Y; Liang W; Li Q; Chen D; Fong W; Kang X; Liu W; Chu ES; Ng QW; Yu J
EBioMedicine; 2024 Feb; 100():104952. PubMed ID: 38176203
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
5. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
7. Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet.
Okada H; Takabatake R; Honda M; Takegoshi K; Yamashita T; Nakamura M; Shirasaki T; Sakai Y; Shimakami T; Nagata N; Takamura T; Tanaka T; Kaneko S
Oncotarget; 2017 Jun; 8(25):39978-39993. PubMed ID: 28591717
[TBL] [Abstract][Full Text] [Related]
8. O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress.
Xu W; Zhang X; Wu JL; Fu L; Liu K; Liu D; Chen GG; Lai PB; Wong N; Yu J
J Hepatol; 2017 Aug; 67(2):310-320. PubMed ID: 28347804
[TBL] [Abstract][Full Text] [Related]
9. TUBB4B is a novel therapeutic target in non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
Yang Z; Gao S; Wong CC; Liu W; Chen H; Shang H; Wu ZY; Xu L; Zhang X; Wong N; Kuang M; Yu J
J Pathol; 2023 May; 260(1):71-83. PubMed ID: 36787097
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
11. Diet and gut microbiome in fatty liver and its associated liver cancer.
Pan Y; Zhang X
J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
[TBL] [Abstract][Full Text] [Related]
12. Portosystemic shunting prevents hepatocellular carcinoma in non-alcoholic fatty liver disease mouse models.
Peloso A; Lacotte S; Gex Q; Slits F; Moeckli B; Oldani G; Tihy M; Hautefort A; Kwak B; Rubbia-Brandt L; Toso C
PLoS One; 2023; 18(12):e0296265. PubMed ID: 38157359
[TBL] [Abstract][Full Text] [Related]
13. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
[TBL] [Abstract][Full Text] [Related]
14. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
15. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
[TBL] [Abstract][Full Text] [Related]
16. New aspects characterizing non-obese NAFLD by the analysis of the intestinal flora and metabolites using a mouse model.
Zhang W; Cheng W; Li J; Huang Z; Lin H; Zhang W
mSystems; 2024 Mar; 9(3):e0102723. PubMed ID: 38421203
[TBL] [Abstract][Full Text] [Related]
17. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
Hymel E; Vlock E; Fisher KW; Farazi PA
PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
19. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
[TBL] [Abstract][Full Text] [Related]
20. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target.
Liu D; Wong CC; Fu L; Chen H; Zhao L; Li C; Zhou Y; Zhang Y; Xu W; Yang Y; Wu B; Cheng G; Lai PB; Wong N; Sung JJY; Yu J
Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]